Vanguard Capital Management
SMMT icon

Vanguard Capital Management’s Summit Therapeutics SMMT Stock Holding History

Vanguard Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.6M Buy
5,734,484
+22,682
+0.4% +$402K ﹤0.01% 1657
2026
Q1 		$108M Buy
+5,711,802
New +$92.4M ﹤0.01% 1431

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's SMMT Position: Q2 2026 in Review

Vanguard Capital Management increased its Summit Therapeutics (SMMT) stake by 0.4% in Q2 2026, buying an estimated $402K and bringing the position to 5,734,484 shares worth $83.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1657.

Vanguard Capital Management first reported a position in SMMT in Q1 2026 and has held it in 2 quarters since. The position peaked at $108M in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Vanguard Capital Management held 5,734,484 shares of Summit Therapeutics worth $83.6M as of Q2 2026.
  • Vanguard Capital Management bought 22,682 Summit Therapeutics shares in Q2 2026, an estimated $402K.
  • Summit Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1657 holding.
  • Vanguard Capital Management first reported a position in Summit Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Summit Therapeutics position peaked at $108M in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.